Kenvue Inc. (KVUE)
| Market Cap | 35.07B |
| Revenue (ttm) | 15.14B |
| Net Income (ttm) | 1.42B |
| Shares Out | 1.92B |
| EPS (ttm) | 0.74 |
| PE Ratio | 24.69 |
| Forward PE | 17.05 |
| Dividend | $0.82 (4.49%) |
| Ex-Dividend Date | Aug 13, 2025 |
| Volume | 5,071,297 |
| Open | 18.18 |
| Previous Close | 18.34 |
| Day's Range | 18.10 - 18.41 |
| 52-Week Range | 17.15 - 25.17 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 24.04 (+31.55%) |
| Earnings Date | Nov 6, 2025 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other... [Read more]
Financial Performance
In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price target is $24.04, which is an increase of 31.55% from the latest price.
News
Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500
Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 d...
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
Kenvue CEO lobbied RFK Jr. not to cite Tylenol as autism cause, WSJ reports
Kenvue's interim Chief Executive Officer Kirk Perry met Robert F. Kennedy Jr. to try and dissuade the U.S. health secretary from including Tylenol as a potential cause of autism in an upcoming report,...
The CEO of Tylenol maker Kenvue lobbied RFK Jr. to not cite the over-the-counter medication as a potential cause of autism in a soon-to-be released report
In a hastily scheduled meeting, Kenvue interim Chief Executive Kirk Perry sought to dissuade the health secretary, arguing there is no clear link.
Dividend Kings: 2 Ideal Buys In 25 "Safer" Of 56 September Dogs
The Dividend Kings list now includes 56 stocks, but only a select few offer fair value and strong yields relative to share price. Five top-yielding Dividend Kings—UVV, CDUAF, NWN, UBSI, and KVUE—curre...
What To Do With These Seven S&P 500 Stocks That Slumped
Tech sector gains masked the underperforming stocks in the S&P 500; selective buying and holding is recommended based on company-specific catalysts and sector positioning. Keurig Dr Pepper and Interna...
S&P 500 Losers: From Lululemon To MGM — What Went Wrong?
During the week ending September 5, the S&P 500 was essentially unchanged, slipping 0.12%. In contrast, several notable S&P 500 stocks fell sharply, driven by a mix of earnings outlook revisions, regu...
Tylenol maker's stock dips after report says RFK Jr.'s HHS plans to link the drug to autism
The U.S. Department of Health and Human Services (HHS) is planning to release a report that will reportedly link autism and acetaminophen use in pregnancy, according to The Wall Street Journal. The de...
Explainer: Is Tylenol safe to take during pregnancy?
U.S. Health Secretary Robert F. Kennedy Jr. plans to announce a link between autism and prenatal exposure to the popular over-the-counter pain and fever medicine Tylenol, sold generically as acetamino...
Dr. Scott Gottlieb reacts to RFK Jr. linking autism to Tylenol
Dr. Scott Gottlieb, fmr. FDA commissioner, joins 'Fast Money' with reaction to RFK Jr. implying Tylenol usage is linked to autism, sending Kenvue stock plummeting.
Kenvue fights back against Tylenol safety concerns as its stock tumbles
Kenvue rushed to the defense of Tylenol, but the stock still suffered a record selloff on news that RFK Jr. will release a report linking the use of acetaminophen during pregnancy to autism.
Tylenol Maker Kenvue's Stock Slumps Following Report RFK Jr. Will Link It to Autism
Shares of Tylenol-maker Kenvue (KVUE) plunged over 9% Friday following a report that federal health officials may link use of the painkiller during pregnancy to autism.
Tylenol-maker shares sink after report says RFK's HHS will link to autism
Shares in the the parent company of Tylenol-maker McNeil Consumer Healthcare sank after a report suggested Robert F. Kennedy Jr.'s HHS will name the drug as a potential cause of autism.
RFK Jr. Report Will Link Autism To Tylenol Use During Pregnancy, Report Says
A promised report from Health and Human Services Secretary Robert F. Kennedy Jr. will claim the use of the common painkiller Tylenol during pregnancy is a potential cause for autism, The Wall Street J...
RFK Jr. To Link Tylenol Use To Autism: Report
Health Secretary Robert F. Kennedy Jr. is preparing to release a report suggesting that the use of a common over-the-counter pain reliever during pregnancy may be tied to a higher risk of autism.
Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy
Shares of Kenvue fell more than 10% on Friday after a report that Health and Human Services Secretary Robert F. Kennedy Jr. will likely link autism to the use of the company's pain medication Tylenol ...
Kennedy and HHS to link use of Tylenol use in pregnancy to autism, WSJ reports
U.S. Health Secretary Robert F. Kennedy Jr. plans to announce that use of over-the-counter pain medication Tylenol in pregnant women is potentially linked to autism in a report that will also suggest ...
Best Dividend Aristocrats For September 2025
Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 A...
Kenvue Can't Be Written Off Yet
Kenvue's fundamental performance looks disastrous, with revenue and margins going in the wrong direction. In that context, a 20x-plus multiple to 2025 adjusted EPS looks far too high. But a new board,...
Kenvue attracts share purchase by activist investor Sachem Head
Band-Aid and Tylenol maker Kenvue attracted the attention of another activist investor in the second quarter, with Sachem Head Capital Management reporting that it bought into the stock.
Kenvue, Inc. (KVUE) Q2 2025 Earnings Call Transcript
Kenvue, Inc. (NYSE:KVUE) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Amit Banati - Chief Financial Officer Kirk L. Perry - Interim CEO & Director Sofya Tsinis - He...
Kenvue meets profit estimates amid strategic review
Kenvue reported a second-quarter profit largely in line with Wall Street estimates on Thursday, amid a strategic review at the consumer health company.
Kenvue Reports Second Quarter 2025 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the second quarter ended June 29, 2025. “Kenvue has a strong portfolio of world-class, category-defining b...
Should You Buy Kenvue Stock At $22?
Although there has been a recent increase of 21% that aligns with the broader market gains, Kenvue (NYSE: KVUE) offers limited investment appeal at its current valuations. Our thorough analysis encomp...
Kenvue Increases Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent in...